Abstract
The Drug Use Disorders Identification Test (DUDIT) is an 11-item self-administered screening instrument developed in Sweden by Anne H. Berman and colleagues to identify drug-related problems, harmful substance consumption, and potential substance dependence in clinical, criminal justice, and general population settings. Designed deliberately as a parallel companion instrument to the World Health Organization’s Alcohol Use Disorders Identification Test (AUDIT), the DUDIT screens for illicit drug consumption patterns and non-medical prescription drug misuse aligned with diagnostic criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV and DSM-5) and the International Classification of Diseases (ICD-10 and ICD-11). The instrument is structured across three primary clinical conceptual domains: drug consumption frequency and quantity (Items 1–4), signs of physiological and psychological dependence (Items 5–6 and 8), and drug-related harmful consequences and problems (Items 7 and 9–11). Items 1 through 9 are scored on a five-point scale (0 to 4), while Items 10 and 11 utilize a three-point historical scale (0, 2, or 4), generating a composite total score ranging from 0 to 44. Extensive psychometric evaluations demonstrate high internal consistency (Cronbach’s alpha typically ranging between .80 and .94) and robust test-retest reliability across diverse international cohorts. Confirmatory and exploratory factor analyses typically reveal either a strong unidimensional general substance severity construct or a correlated two-factor framework delineating drug consumption habits from dependence symptoms and negative consequences. DUDIT provides reliable clinical utility through established cut-off thresholds, offering distinct sensitivities and specificities for men and women.
Keywords
Drug Use Disorders Identification Test, DUDIT, substance use disorder, screening instrument, psychometrics, drug dependence, harmful drug use, clinical assessment, addiction psychiatry, self-report screening.
Authors
The Drug Use Disorders Identification Test was developed at the Karolinska Institutet in Stockholm, Sweden. The primary authors involved in the conceptualization, validation, and standard manualization of the instrument are:
- Anne H. Berman, Ph.D. — Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden; Department of Psychology, Uppsala University, Uppsala, Sweden.
- Hans Bergman, Ph.D. — Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Center for Healthcare Sciences, Stockholm, Sweden.
- Torkel Palmstierna, M.D., Ph.D. — Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; St. Olavs University Hospital, Trondheim, Norway.
- Fabian Schlyter, M.Sc. — Prison and Probation Service, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet.
Purpose
The principal objective of the Drug Use Disorders Identification Test (DUDIT) is to provide clinicians, researchers, and public health practitioners with a brief, standardized, and cost-effective screening tool capable of identifying the full continuum of illicit drug consumption, hazardous patterns of drug use, and clinically manifest drug dependence. Prior to the introduction of the DUDIT in the early 2000s, clinical assessment of psychoactive substance use disorders suffered from an asymmetric methodological divide: while alcohol misuse was systematically captured using the standardized AUDIT framework, screening for other psychoactive substances relied on fragmented, substance-specific surveys, lengthier structured clinical interviews, or non-standardized intake questionnaires that lacked psychometric rigor.
From an applied clinical perspective, the DUDIT serves as a primary triaging mechanism within diverse healthcare and institutional environments, including community mental health clinics, emergency departments, general primary care, forensic inpatient facilities, and correctional institutions. Early identification of substance use problems is critical because individuals experiencing emerging drug-related harms frequently interact with healthcare systems for collateral physical or psychiatric complaints without directly disclosing their substance habits. By offering an objective, non-pejorative self-administered or interview-based instrument, the DUDIT facilitates early detection and prompt referral to motivational interviewing, harm reduction initiatives, or specialized addiction treatment programs.
In epidemiological and psychiatric research, the DUDIT enables cross-population comparisons by standardizing how drug severity is quantified. Because the instrument covers all psychoactive substances other than alcohol—including cannabis, amphetamines, cocaine, heroin, non-prescribed sedatives, opioids, and synthetic compounds—it standardizes measurement across poly-substance using cohorts where isolated drug-specific metrics often fail to capture cumulative clinical severity.
Psychological Construct
The psychological and behavioral construct quantified by the DUDIT is substance use severity, conceptualized as a multi-layered continuum spanning sub-clinical experimentation, hazardous drug intake, harmful consequences, and severe psychological and physiological dependence. Rather than operationalizing substance involvement solely through biochemical markers or consumption metrics, the DUDIT captures the behavioral, affective, and functional disruptions associated with substance pathology.
The construct encompasses three primary interrelated dimensions:
- Consumption Patterns (Items 1–4): This dimension assesses the frequency of illicit drug intake, the prevalence of polydrug consumption (using multiple substances simultaneously), daily dosing patterns, and the frequency of experiencing heavy intoxication. Polydrug exposure and heavy intoxication serve as primary behavioral indicators of hazardous consumption, escalating the immediate risk of accidental overdose, acute toxicities, and cognitive impairment.
- Dependence Symptoms (Items 5, 6, and 8): Grounded in classic neurobiological models of addiction, this dimension evaluates core diagnostic hallmarks of chemical dependence, including intense craving or psychological compulsion (Item 5), impaired control over initiation and cessation of drug intake (Item 6), and physiological withdrawal relief or “eye-opener” consumption behaviors (Item 8). These markers reflect neuroadaptive changes within mesolimbic reward circuitries and executive regulatory systems.
- Harmful Consequences and Negative Sequelae (Items 7, 9, 10, and 11): This dimension captures the negative secondary fallout of drug misuse across social, interpersonal, occupational, physical, and moral spheres. It measures functional neglect of developmental or professional responsibilities (Item 7), subjective guilt or cognitive dissonance following drug use (Item 9), physical or psychological trauma inflicted upon the self or third parties (Item 10), and external concern, social intervention, or medical warnings voiced by family members, peers, or medical professionals (Item 11).
Theoretical Framework
The theoretical framework underlying the DUDIT draws from syndromic models of substance dependence developed by Griffith Edwards and Milton M. Gross, alongside diagnostic formulations embedded within the American Psychiatric Association’s DSM and the World Health Organization’s ICD systems.
Edwards and Gross posited that alcohol and drug dependence constitute a distinct, psychobiological syndrome characterized by a narrowing of the personal behavioral repertoire, salience of substance-seeking behavior, neurochemical tolerance, repeated withdrawal episodes, and subjective awareness of a compulsion to use. The DUDIT operationalizes these theoretical tenets into concrete self-report behaviors. The scale aligns closely with the public health screening model popularized by the World Health Organization, which conceptualizes substance misuse along a tiered risk pyramid:
- Low-Risk / Abstinence: Individuals scoring zero or below clinical thresholds who require no active clinical intervention.
- Hazardous Use: Patterns of use that increase the risk of harmful physical or mental consequences, responsive to brief motivational interventions and educational feedback.
- Harmful Use: Clear patterns of drug use causing demonstrable psychological or somatic damage, necessitating targeted outpatient intervention.
- Substance Dependence: Severe, chronic cognitive and behavioral dysregulation requiring comprehensive, specialized addiction treatment.
Cognitive-behavioral models of addiction also support the inclusion of Item 9 (guilt feelings). The cognitive dissonance experienced between an individual’s personal values and their substance-driven behaviors serves as a critical indicator of functional impairment and frequently precipitates either escalation of use to cope with distress or, conversely, readiness for therapeutic change.
Validity
The psychometric validity of the DUDIT has been evaluated across clinical detoxification services, prison populations, probation services, university cohorts, and general community samples across North America, Europe, and Asia.
Construct and Criterion Validity
In the seminal validation investigation conducted by Berman et al. (2005), the DUDIT demonstrated high sensitivity and specificity against formal clinical diagnoses derived from the Structured Clinical Interview for DSM-IV (SCID-I). When differentiating between individuals with diagnosed substance dependence and non-dependent community controls, receiver operating characteristic (ROC) analyses yielded an Area Under the Curve (AUC) ranging from .93 to .99. Within criminal justice settings, sensitivity was documented at .90 and specificity at .88 using an optimal cut-off score of 6 for men. Among women, a cut-off score of 2 yielded optimal diagnostic balance (sensitivity .86, specificity .83), reflecting differential epidemiological and biological consumption thresholds.
Convergent and Discriminant Validity
Convergent validity has been established through substantial, statistically significant correlations with alternative standardized substance assessment instruments, including the Addiction Severity Index (ASI drug composite score: r = .65 to .78) and the Drug Abuse Screening Test (DAST-10 and DAST-20: r = .74 to .85). Furthermore, scores on the DUDIT correlate positively with objective biological markers, such as urine toxicology screens for cannabis, stimulants, and opiates. Discriminant validity is supported by lower correlations with measures of pure alcohol dependence (when non-substance cross-addiction is controlled) and general somatic health scales, confirming that the DUDIT captures drug-specific pathology rather than generalized emotional or physical distress.
Reliability
The DUDIT exhibits strong reliability across a spectrum of populations and clinical settings. Internal consistency, measured via Cronbach’s alpha, systematically exceeds standard psychometric criteria for clinical instruments:
- In the original Swedish validation sample (Berman et al., 2005), Cronbach’s alpha was .94 for the total clinical and correctional cohort, .80 within a pure criminal justice sub-sample, and .88 among individuals in detoxification treatment.
- International adaptations, including the English, Spanish, German, French, and Japanese versions, report alpha coefficients ranging between .84 and .93 in addiction treatment, psychiatric, and community samples.
- Item-total correlations consistently range from .52 to .81, indicating that each item contributes meaningfully to the overall measurement of substance severity.
Test-retest reliability has been examined across diverse test-retest intervals (spanning from one week to one month). Intraclass correlation coefficients (ICC) typically exceed .85, demonstrating stability in non-treatment-seeking cohorts while remaining sensitive to genuine behavioral changes during structured clinical interventions.
Factor Analysis
Structural evaluations using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) have examined the internal structural validity of the DUDIT across numerous languages and clinical cohorts.
Initial principal components and exploratory factor analyses conducted by Berman et al. suggested a predominantly unidimensional solution accounting for over 50% to 65% of the total variance, with all 11 items loading substantially (> .50) onto a single primary factor representing overall drug-related problem severity. Consequently, reporting a single global composite score is empirically supported for general screening.
However, subsequent confirmatory factor analyses in diverse international clinical samples frequently demonstrate superior goodness-of-fit indices for a correlated two-factor model:
- Factor 1: Drug Consumption / Habits (Items 1–4): Captures behavioral intake frequency, dosage, polydrug misuse, and acute intoxication levels. Factor loadings typically range between .62 and .88.
- Factor 2: Drug-Related Dependence and Consequences (Items 5–11): Captures neuroadaptive dependence symptoms, functional impairment, guilt, and social/interpersonal harms. Factor loadings for this dimension typically range between .58 and .84.
CFA fit metrics for this correlated two-factor model across published studies regularly demonstrate acceptable to excellent fit: Comparative Fit Index (CFI) > .95, Tucker-Lewis Index (TLI) > .94, and Root Mean Square Error of Approximation (RMSEA) < .06.
Instrument / Measurement Tool
- Tool Name: Drug Use Disorders Identification Test (DUDIT)
- Assessment Type: Psychological screening instrument / brief self-report questionnaire (can also be clinician-administered via structured interview)
- Target Population: Adolescents and adults (typically ages 15+) suspected of hazardous or harmful drug use, clinical patients, correctional populations, and community cohorts
- Administration Time: Approximately 3 to 5 minutes
- Number of Items: 11 items
- Substance Scope: All illicit drugs and non-prescribed medications/pharmaceuticals (cannabis, cocaine, amphetamines, heroin/opiates, hallucinogens, sedatives, inhalants, etc.), excluding alcohol
- Item Response Formats:
- Items 1–2: 5-point Likert scale (0 = Never, 1 = Once a month or less often, 2 = 2-4 times a month, 3 = 2-3 times a week, 4 = 4 times a week or more often)
- Item 3: 5-point numeric frequency scale (0 = 0, 1 = 1-2, 2 = 3-4, 3 = 5-6, 4 = 7 or more)
- Items 4–9: 5-point temporal frequency scale (0 = Never, 1 = Less often than once a month, 2 = Every month, 3 = Every week, 4 = Daily or almost daily)
- Items 10–11: 3-point categorical occurrence scale (0 = No, 2 = Yes, but not over the past year, 4 = Yes, over the past year)
- Scoring and Cut-off Thresholds:
- Total Score Range: 0 to 44 points (sum of all 11 items)
- Drug-Related Problems Threshold (Hazardous/Harmful Use): Total score ≥ 6 for men; Total score ≥ 2 for women
- Probable Drug Dependence Threshold: Total score ≥ 25 (indicative of severe substance dependence warranting full diagnostic workup and specialized clinical care)
Permissions & Fee and Test Year
The Drug Use Disorders Identification Test was formally published in 2005. Designed as a public-domain public health screening instrument patterned directly after the World Health Organization’s AUDIT, the DUDIT is made freely available for clinical, educational, and academic research purposes without licensing fees or royalty charges.
The developers (Karolinska Institutet) encourage widespread clinical and empirical utilization, provided proper bibliographic citation is maintained. While free to administer, modifications to item text, scoring structures, or standardized translations must be validated psychometrically to preserve the instrument’s diagnostic properties. Detailed manuals and user guidelines have been disseminated through academic publications and the Karolinska Institutet website.
References
- Berman, A. H., Bergman, H., Palmstierna, T., & Schlyter, F. (2005). Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. European Addiction Research, 11(1), 22–31. https://doi.org/10.1159/000081413
- Berman, A. H., Palmstierna, T., Källmén, H., & Bergman, H. (2007). The Karolinska Cognitive and Behavioral Interventions Program for young offenders: A 2-year follow-up study with focus on substance abuse. Journal of Substance Abuse Treatment, 32(4), 415–424. https://doi.org/10.1016/j.jsat.2006.10.005
- Hildebrand, M. (2015). The psychometric properties of the Drug Use Disorders Identification Test (DUDIT): A review of recent research. Journal of Substance Abuse Treatment, 53, 52–59. https://doi.org/10.1016/j.jsat.2015.01.008
- Saunders, J. B., Aasland, O. G., Babor, T. F., de la Fuente, J. R., & Grant, M. (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction, 88(6), 791–804. https://doi.org/10.1111/j.1360-0443.1993.tb02093.x
- Voluse, A. C., Gioia, C. J., Sobell, L. C., Dum, M., Sobell, M. B., & Simco, E. R. (2012). Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) with substance abusers in outpatient settings. Addictive Behaviors, 37(1), 36–41. https://doi.org/10.1016/j.addbeh.2011.08.011
Items of the Scale
Response scale instructions:
Items 1-2: 0 = Never, 1 = Once a month or less often, 2 = 2-4 times a month, 3 = 2-3 times a week, 4 = 4 times a week or more often; Item 3: 0 = 0, 1 = 1-2, 2 = 3-4, 3 = 5-6, 4 = 7 or more; Items 4-9: 0 = Never, 1 = Less often than once a month, 2 = Every month, 3 = Every week, 4 = Daily or almost daily; Items 10-11: 0 = No, 2 = Yes, but not over the past year, 4 = Yes, over the past year.
- How often do you use drugs other than alcohol?
[0] Never | [1] Once a month or less often | [2] 2-4 times a month | [3] 2-3 times a week | [4] 4 times a week or more often
- Do you use more than one type of drug on the same occasion?
[0] Never | [1] Once a month or less often | [2] 2-4 times a month | [3] 2-3 times a week | [4] 4 times a week or more often
- How many times do you take drugs on a typical day when you use drugs?
[0] 0 | [1] 1-2 | [2] 3-4 | [3] 5-6 | [4] 7 or more
- How often are you influenced heavily by drugs?
[0] Never | [1] Less often than once a month | [2] Every month | [3] Every week | [4] Daily or almost daily
- Over the past year, have you felt that your longing for drugs was so strong that you could not resist it?
[0] Never | [1] Less often than once a month | [2] Every month | [3] Every week | [4] Daily or almost daily
- Has it happened over the past year that you have not been able to stop taking drugs once you started?
[0] Never | [1] Less often than once a month | [2] Every month | [3] Every week | [4] Daily or almost daily
- How often over the past year have you taken drugs and then neglected to do something you should have done?
[0] Never | [1] Less often than once a month | [2] Every month | [3] Every week | [4] Daily or almost daily
- How often over the past year have you needed to take a drug the morning after heavy drug use the day before?
[0] Never | [1] Less often than once a month | [2] Every month | [3] Every week | [4] Daily or almost daily
- How often over the past year have you had guilt feelings or a bad conscience because of your drug use?
[0] Never | [1] Less often than once a month | [2] Every month | [3] Every week | [4] Daily or almost daily
- Have you or has someone else been hurt (mentally or physically) because you used drugs?
[0] No | [2] Yes, but not over the past year | [4] Yes, over the past year
- Has a relative or a friend, a doctor or a nurse, or anyone else, been worried about your drug use or said to you that you should stop using drugs?
[0] No | [2] Yes, but not over the past year | [4] Yes, over the past year